Scarpitta Allan, Hacker Ulrich T, Büning Hildegard, Boyer Olivier, Adriouch Sahil
UNIROUEN, INSERM, U1234, Pathophysiology, Autoimmunity, Neuromuscular Diseases and Regenerative Therapies, Normandie University, Rouen, France.
Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious Diseases, University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, Leipzig, Germany.
Front Oncol. 2021 Aug 19;11:731598. doi: 10.3389/fonc.2021.731598. eCollection 2021.
Cancer remains the second most common cause of death worldwide affecting around 10 million patients every year. Among the therapeutic options, chemotherapeutic drugs are widely used but often associated with side effects. In addition, toxicity against immune cells may hamper anti-tumor immune responses. Some chemotherapeutic drugs, however, preserve immune functions and some can even stimulate anti-tumor immune responses through the induction of immunogenic cell death (ICD) rather than apoptosis. ICD stimulates the immune system by several mechanisms including the release of damage-associated molecular patterns (DAMPs) from dying cells. In this review, we will discuss the consequences of inducing two recently characterized forms of ICD, i.e., pyroptosis and necroptosis, in the tumor microenvironment (TME) and the perspectives they may offer to increase the immunogenicity of the so-called cold tumors and to stimulate effective anti-tumor immune responses.
癌症仍然是全球第二大常见死因,每年影响约1000万患者。在治疗选择中,化疗药物被广泛使用,但常常伴有副作用。此外,对免疫细胞的毒性可能会阻碍抗肿瘤免疫反应。然而,一些化疗药物能够保留免疫功能,有些甚至可以通过诱导免疫原性细胞死亡(ICD)而非凋亡来刺激抗肿瘤免疫反应。ICD通过多种机制刺激免疫系统,包括从垂死细胞中释放损伤相关分子模式(DAMPs)。在这篇综述中,我们将讨论在肿瘤微环境(TME)中诱导两种最近被鉴定的ICD形式,即细胞焦亡和坏死性凋亡的后果,以及它们在增加所谓冷肿瘤的免疫原性和刺激有效的抗肿瘤免疫反应方面可能提供的前景。